Effect of Orlistat comprehensive intervention on lipoprotein(a) and glycolipid metabolism and hepatorenal function in overweight or obese patients with  polycystic ovary syndrome

doi:10.3969/j.issn.1006-7795.2023.04.007

Abstract

Abstract: Objective To access the effect of Orlistat combined with drospirenone/ethinylestradiol tablets (DRSP/EE) on the lipoprotein(a), glycolipid metabolism and hepatorenal function compared to DRSP/EE-alone in overweight or obese patients with polycystic ovary syndrome (PCOS). Methods We conducted a randomized controlled trial involving 69 overweight or obese PCOS patients. In principle of comparable baseline characteristics between groups, all participants were randomly assigned into two groups in a 1∶2 ratio, who received DRSP/EE alone as the control group(n=23) and DRSP/EE plus Orlistat as the observation group(n=46) for 12 weeks. Both groups got the same comprehensive intervention regarding diet and physical activities, which is standardized in Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Changes in cardiovascular risk factors including lipoprotein(a)［Lp(a)］, weight, waist circumference (WC), total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), fasting plasma glucose (FPG), fasting insulin (FINS), homocysteine (HCY), and uric acid (UA) were observed before and after different regiments. Results After 12 weeks of treatment, the Lp(a), LDL-C, FPG, and body weight levels of the observation group decreased significantly compared with the control group (P<0.05). The levels of WC, TC, FINS, UA, and HCY in the observation group decreased, and the FINS level increased in the control group, but there was no significant statistical significance (P>0.05). HDL-C and TG in the two groups were higher than those before treatment, and the difference was not statistically significant (P>0.05). Conclusions Olistat combined with DRSP/EE can reduce the levels of Lp(a), LDL-C, FPG, and body weight in overweight or obese PCOS patients, which provides evidence for the choice of rational drug use in clinical practice.

Key words: polycystic ovary syndrome, overweight or obesity, lipoprotein(a), Orlistat, drospirenone/ethinylestradiol tablets

CLC Number:

Zhang Mingzhen, Ruan Xiangyan, Min Min, Alfred O. Mueck. Effect of Orlistat comprehensive intervention on lipoprotein(a) and glycolipid metabolism and hepatorenal function in overweight or obese patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2023, 44(4): 544-549.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.04.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I4/544

References

［1］ Joham A E, Norman R J, Stener-Victorin E, et al. Polycystic ovary syndrome［J］. Lancet Diabetes Endocrinol, 2022, 10(9): 668-680.
［2］ Wekker V, Van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis［J］. Hum Reprod Update, 2020, 26(6): 942-960.
［3］ Aziz M, Sidelmann J J, Faber J, et al. Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes［J］. Acta Obstet Gynecol Scand, 2015, 94(10): 1082-1089.
［4］ Gencer B, Kronenberg F, Stroes E S, et al. Lipoprotein(a): the revenant［J］. Eur Heart J, 2017, 38(20): 1553-1560.
［5］ Yilmaz M, Biri A, Bukan N, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome［J］. Gynecol Endocrinol, 2005, 20(5): 258-263.
［6］中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南［J］. 中华妇产科杂志, 2018, 53(1): 2-6.
［7］ Teede H J, Misso M L, Costello M F, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome［J］. Clin Endocrinol (Oxf), 2018, 89(3): 251-268.
［8］阮祥燕, 谷牧青. 多囊卵巢综合征的诊断治疗与管理［J］. 中国临床医生杂志, 2021, 49(1): 3-7, 2.
［9］ Saunders K H, Umashanker D, Igel L I, et al. Obesity pharmacotherapy［J］. Med Clin North Am, 2018, 102(1): 135-148.
［10］中国肥胖问题工作组. 中国成人超重和肥胖症预防与控制指南(节录)［J］. 营养学报, 2004(1): 1-4.
［11］ Glintborg D, Rubin K H, Nybo M, et al. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome［J］. Cardiovasc Diabetol, 2018, 17(1): 37.
［12］胡芸, 蒋凤艳. 肥胖型多囊卵巢综合征与心血管疾病的研究现状［J］. 医学综述, 2008, 14(2): 287-289.
［13］ Bousmpoula A, Kouskouni E, Benidis E, et al. Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles［J］. Gynecol Endocrinol, 2018, 34(2): 153-156.
［14］ Kamstrup P R. Lipoprotein(a) and cardiovascular disease［J］. Clin Chem, 2021, 67(1): 154-166.
［15］ Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism［J］. Contraception, 2005, 71(6): 409-416.
［16］ Cegla J, Neely R D G, France M, et al. HEART UK consensus statement on Lipoprotein(a): a call to action［J］. Atherosclerosis, 2019, 291: 62-70.
［17］ Rössner S Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group［J］. Obes Res, 2000, 8(1): 49-61.
［18］ Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study［J］. Int J Obes Relat Metab Disord, 2001, 25(11): 1713-1721.
［19］ Kumar A, Chauhan S. Pancreatic lipase inhibitors: the road voyaged and successes［J］. Life Sci, 2021, 271: 119115.
［20］ Saleh A, ElFayoumi H M, Youns M, et al. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions［J］. Naunyn Schmiedebergs Arch Pharmacol, 2019, 392(2): 165-175.
［21］ Zhou Y H, Ma X Q, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials［J］. PLoS One, 2012, 7(6): e39062.
［22］ Panda S R, Jain M, Jain S, et al. Effect of orlistat versus metformin in various aspects of polycystic ovarian syndrome: a systematic review of randomized control trials［J］. J Obstet Gynaecol India, 2018, 68(5): 336-343.
［23］ Jindal A, Brietzke S, Sowers J R. Obesity and the cardiorenal metabolic syndrome: therapeutic modalities and their efficacy in improving cardiovascular and renal risk factors［J］. Cardiorenal Med, 2012, 2(4): 314-327.
［24］ Chanoine J P, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial［J］. JAMA, 2005, 293(23): 2873-2883.
［25］ Patni N, Quittner C, Garg A. Orlistat therapy for children with type 1 hyperlipoproteinemia: a randomized clinical trial［J］. J Clin Endocrinol Metab, 2018, 103(6): 2403-2407.
［26］ Li L, Zhang R Q, Zeng J, et al. Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study［J］. BMC Womens Health, 2020, 20(1): 39.
［27］ De Medeiros S F. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome［J］. Reprod Biol Endocrinol, 2017, 15(1): 93.
［28］ Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome［J］. J Endocrinol Invest, 2013, 36(5): 358-363.
［29］ Beller J P, McCartney C R. Cardiovascular risk and combined oral contraceptives: clinical decisions in settings of uncertainty［J］. Am J Obstet Gynecol, 2013, 208(1): 39-41.

Effect of Orlistat comprehensive intervention on lipoprotein(a) and glycolipid metabolism and hepatorenal function in overweight or obese patients with polycystic ovary syndrome

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics

Comments